{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:12:23Z","timestamp":1779286343795,"version":"3.51.4"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To assess patient characteristics, treatment patterns, botulinum toxin type-A (BoNT-A) costs\u00a0and describe safety in adults with spasticity who switched from onabotulinumtoxinA to abobotulinumtoxinA.\n                    <jats:bold>Materials\u00a0&amp; methods:<\/jats:bold>\n                    Chart data from three US-based treatment centers was collected in patients aged \u226518\u00a0years with upper limb (ULS), lower limb (LLS)\u00a0or ULS and LLS (ULS\u00a0+\u00a0LLS) spasticity. Eligible patients had \u22652 onabotulinumtoxinA treatment cycles before switching to abobotulinumtoxinA; they were followed for three additional abobotulinumtoxinA treatment cycles. A\n                    <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                    analysis of estimated drug costs was conducted.\n                    <jats:bold>Results:<\/jats:bold>\n                    Eighty-eight patients (mean age 44.9\u00a0years; 62.5% male) switched from onabotulinumtoxinA to abobotulinumtoxinA; in 84 (95.5%), the switch was due to \u2018medical need\/effectiveness not achieved.\u2019\u00a0Most common spasticity etiologies were cerebral palsy (43.2%) and stroke (25.0%). Fifty-one patients (58.0%) had bilateral spasticity with a mean\u00a0\u00b1\u00a0SD of 5.1\u00a0\u00b1\u00a02.2 muscles injected at each visit over the 5-injection-cycle treatment period. No adverse events were reported following switching. Mean estimated cost per visit was $2731 with onabotulinumtoxinA and $1452 with abobotulinumtoxinA.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In this real-world study, patients with ULS, LLS\u00a0or ULS\u00a0+\u00a0LLS who were switched from onabotulinumtoxinA to abobotulinumtoxinA continued for \u22653 treatment cycles without any reported adverse events. Switching resulted in lower estimated BoNT-A costs.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0181","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:34:27Z","timestamp":1777631667000},"source":"Crossref","is-referenced-by-count":0,"title":["Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers"],"prefix":"10.57264","volume":"15","author":[{"given":"Nate","family":"Way","sequence":"first","affiliation":[{"name":"Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA\u00a019301,\u00a0USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Dabrowski","sequence":"additional","affiliation":[{"name":"Beaumont Health, Royal Oak, MI\u00a048073, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Paulin","sequence":"additional","affiliation":[{"name":"The Center for Tone Management of the Main Line, Paoli, PA\u00a019301, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Taylor","sequence":"additional","affiliation":[{"name":"OrthoNeuro, New Albany, OH\u00a043054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Madden","sequence":"additional","affiliation":[{"name":"Ipsen, Cambridge, MA\u00a002142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Mann","sequence":"additional","affiliation":[{"name":"Ipsen, Cambridge, MA\u00a002142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Ipsen, Cambridge, MA\u00a002142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"7","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1191\/0269215502cr546oa","article-title":"The associated reaction rating scale: a clinical tool to measure associated reactions in the hemiplegic upper limb","volume":"16","author":"Macfarlane A","year":"2002","unstructured":"Macfarlane A, Turner-Stokes L, De Souza L. The associated reaction rating scale: a clinical tool to measure associated reactions in the hemiplegic upper limb. Clin. Rehabil. 16(7), 726\u2013735 (2002).","journal-title":"Clin. Rehabil."},{"issue":"3","key":"e_1_3_8_4_2","first-page":"401","article-title":"Managing spasticity with drugs","volume":"46","author":"Simon O","year":"2010","unstructured":"Simon O, Yelnik AP. Managing spasticity with drugs. Eur. J. Phys. Rehabil. Med. 46(3), 401\u2013410 (2010).","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"354906","DOI":"10.1155\/2014\/354906","article-title":"Pathophysiology of spasticity: implications for neurorehabilitation","volume":"2014","author":"Trompetto C","year":"2014","unstructured":"Trompetto C, Marinelli L, Mori L Pathophysiology of spasticity: implications for neurorehabilitation. Biomed. Res. Int. 2014, 354906 (2014).","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: pharmacological and interventional approaches","volume":"25","author":"Chang E","year":"2013","unstructured":"Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A review of spasticity treatments: pharmacological and interventional approaches. Crit. Rev. Phys. Rehabil. Med. 25(1\u20132), 11\u201322 (2013).","journal-title":"Crit. Rev. Phys. Rehabil. Med."},{"issue":"6","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0269215515593391","article-title":"Common goal areas in the treatment of upper limb spasticity: a multicentre analysis","volume":"30","author":"Ashford S","year":"2016","unstructured":"Ashford S, Fheodoroff K, Jacinto J, Turner-Stokes L. Common goal areas in the treatment of upper limb spasticity: a multicentre analysis. Clin. Rehabil. 30(6), 617\u2013622 (2016).","journal-title":"Clin. Rehabil."},{"issue":"2","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3121\/cmr.2007.716","article-title":"Botulinum toxin in poststroke spasticity","volume":"5","author":"Ozcakir S","year":"2007","unstructured":"Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin. Med. Res. 5(2), 132\u2013138 (2007).","journal-title":"Clin. Med. Res."},{"key":"e_1_3_8_9_2","volume-title":"Spasticity in Children and Young People with Non-Progressive Brain Disorders: Management of Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal Complications","author":"National Collaborating Centre for Women's Children's Health","year":"2012","unstructured":"National Collaborating Centre for Women's Children's Health. National Institute for Health and Clinical Excellence: guidance. In: Spasticity in Children and Young People with Non-Progressive Brain Disorders: Management of Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal Complications. RCOG Press, National Collaborating Centre for Women's and Children's Health, London (2012)."},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome","volume":"67","author":"Esquenazi A","year":"2013","unstructured":"Esquenazi A, Albanese A, Chancellor MB Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon 67, 115\u2013128 (2013).","journal-title":"Toxicon"},{"issue":"1","key":"e_1_3_8_11_2","first-page":"Cd003469","article-title":"Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)","volume":"2010","author":"Hoare BJ","year":"2010","unstructured":"Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst. Rev. 2010(1), Cd003469 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"e_1_3_8_12_2","first-page":"86","article-title":"Health care resource utilization and costs among patients with spasticity or cervical dystonia","volume":"30","author":"Hull M","year":"2024","unstructured":"Hull M, Danchenko N, Anupindi VR, DeKoven M, He J, Bouchard J. Health care resource utilization and costs among patients with spasticity or cervical dystonia. J. Manag. Care Spec. Pharm. 30(1), 86\u201397 (2024).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"19","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson DM","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86(19), 1818\u20131826 (2016).","journal-title":"Neurology"},{"issue":"19","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000311391.00944.c4","article-title":"Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson DM","year":"2008","unstructured":"Simpson DM, Gracies JM, Graham HK Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19), 1691\u20131698 (2008).","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7861\/clinmedicine.9-2-101","article-title":"Spasticity in adults: management of botulinum toxin","volume":"9","author":"Allan R","year":"2009","unstructured":"Allan R. Spasticity in adults: management of botulinum toxin. Clin. Med. (Lond) 9(2), 101 (2009).","journal-title":"Clin. Med. (Lond)"},{"issue":"1","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ptj\/64.1.35","article-title":"Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness","volume":"64","author":"Holden MK","year":"1984","unstructured":"Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys. Ther. 64(1), 35\u201340 (1984).","journal-title":"Phys. Ther."},{"issue":"1","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5603\/PJNNS.a2020.0004","article-title":"Real-world effectiveness of abobotulinumtoxinA (Dysport\u00ae) in adults with upper limb spasticity in routine clinical practice: an observational study","volume":"54","author":"Sarzy\u0144ska-D\u0142ugosz I","year":"2020","unstructured":"Sarzy\u0144ska-D\u0142ugosz I, Szczepa\u0144ska-Szerej A, Dru\u017cd\u017c A Real-world effectiveness of abobotulinumtoxinA (Dysport\u00ae) in adults with upper limb spasticity in routine clinical practice: an observational study. Neurol. Neurochir. Pol. 54(1), 90\u201399 (2020).","journal-title":"Neurol. Neurochir. Pol."},{"issue":"12","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field M","year":"2018","unstructured":"Field M, Splevins A, Picaut P AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients. Toxins 10(12), 535 (2018).","journal-title":"Toxins"},{"key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4939-0261-3_2","volume-title":"Clinical Applications of Botulinum Neurotoxin","author":"Pickett A","year":"2014","unstructured":"Pickett A. Botulinum toxin as a clinical product: manufacture and pharmacology. In: Clinical Applications of Botulinum Neurotoxin. Foster KA (Ed.). Springer New York, NY, USA 7\u201349 (2014)."},{"key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: a marvel of protein design","volume":"79","author":"Montal M","year":"2010","unstructured":"Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79, 591\u2013617 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"588395","DOI":"10.3389\/fneur.2020.588395","article-title":"Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy","volume":"11","author":"Hefter H","year":"2020","unstructured":"Hefter H, Schomaecker I, Schomaecker M, Samadzadeh S. Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy. Front. Neurol. 11, 588395 (2020).","journal-title":"Front. Neurol."},{"issue":"1","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/nau.23291","article-title":"Switch to abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of onabotulinum toxin A failed","volume":"37","author":"Bottet F","year":"2018","unstructured":"Bottet F, Peyronnet B, Boissier R Switch to abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of onabotulinum toxin A failed. Neurourol. Urodyn. 37(1), 291\u2013297 (2018).","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2340\/16501977-2550","article-title":"Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety and efficacy evaluation","volume":"51","author":"Dursun N","year":"2019","unstructured":"Dursun N, Akarsu M, Gokbel T, Akyuz M, Karacan C, Dursun E. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety and efficacy evaluation. J. Rehabil. Med. 51(5), 390\u2013394 (2019).","journal-title":"J. Rehabil. Med."},{"issue":"3","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/toxins17030103","article-title":"Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity","volume":"17","author":"Leblong E","year":"2025","unstructured":"Leblong E, Piette P, Anne C Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity. Toxins (Basel) 17(3), 103 (2025).","journal-title":"Toxins (Basel)"},{"issue":"1","key":"e_1_3_8_25_2","article-title":"A Retrospective Analysis Evaluating a Switch of AbobotulinumtoxinA for the Treatment of Adult Spasticity in Patients Previously Treated with Onabotulinumtoxina [abstract]","volume":"12","author":"Bowers D","year":"2020","unstructured":"Bowers D. A Retrospective Analysis Evaluating a Switch of AbobotulinumtoxinA for the Treatment of Adult Spasticity in Patients Previously Treated with Onabotulinumtoxina [abstract]. In: PM R. 12(Suppl. 1), (2020).","journal-title":"In: PM R."},{"key":"e_1_3_8_26_2","volume-title":"Poster 36, TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins","author":"Dursun NAM","year":"2019","unstructured":"Dursun NAM, Gokbel T, Akyuz M, Karacan C, Dursun E. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety evaluation. Poster 36, TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. Copenhagen, Denmark (16\u201319 January 2019)."},{"issue":"9","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/toxins15090532","article-title":"A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity","volume":"15","author":"Bezzina C","year":"2023","unstructured":"Bezzina C, Degtiar V, Danchenko N A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins (Basel) 15(9), 532 (2023).","journal-title":"Toxins (Basel)"},{"issue":"19","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson DM","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19), 1699\u20131706 (2008).","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mdc3.13696","article-title":"Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia","volume":"10","author":"Samotus O","year":"2023","unstructured":"Samotus O, Jog M. Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia. Mov. Disord. Clin. Pract. 10(5), 756\u2013763 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"e_1_3_8_30_2","volume-title":"StatPearls (StatPearls Publishing Copyright \u00a9 2023)","author":"Harb A","year":"2023","unstructured":"Harb A, Kishner S. Modified Ashworth Scale. In: StatPearls (StatPearls Publishing Copyright \u00a9 2023), StatPearls Publishing LLC, FL, USA (2023)."},{"issue":"4","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0269215508101742","article-title":"Goal attainment scaling (GAS) in rehabilitation: a practical guide","volume":"23","author":"Turner-Stokes L","year":"2009","unstructured":"Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin. Rehabil. 23(4), 362\u2013370 (2009).","journal-title":"Clin. Rehabil."},{"issue":"1","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/toxins10010018","article-title":"Ultrasound guidance for botulinum neurotoxin chemodenervation procedures","volume":"10","author":"Alter KE","year":"2017","unstructured":"Alter KE, Karp BI. Ultrasound guidance for botulinum neurotoxin chemodenervation procedures. Toxins (Basel) 10(1), 18 (2017).","journal-title":"Toxins (Basel)"},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins13040249","article-title":"Ergonomic recommendations in ultrasound-guided botulinum neurotoxin chemodenervation for spasticity: an international expert group opinion","volume":"13","author":"Lagnau P","year":"2021","unstructured":"Lagnau P, Lo A, Sandarage R Ergonomic recommendations in ultrasound-guided botulinum neurotoxin chemodenervation for spasticity: an international expert group opinion. Toxins (Basel) 13(4), 249 (2021).","journal-title":"Toxins (Basel)"},{"issue":"4","key":"e_1_3_8_34_2","first-page":"361","article-title":"[Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A: results of the German-Austrian subgroup of the ULIS-II study]","volume":"90","author":"Fheodoroff K","year":"2019","unstructured":"Fheodoroff K, Dressler D, Woldag H [Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A: results of the German-Austrian subgroup of the ULIS-II study]. Nervenarzt 90(4), 361\u2013370 (2019).","journal-title":"Nervenarzt"},{"issue":"2","key":"e_1_3_8_35_2","first-page":"100129","article-title":"Goal attainment: a clinically meaningful measure of success of botulinum toxin-a treatment for lower limb spasticity in ambulatory patients","volume":"3","author":"Choudhry S","year":"2021","unstructured":"Choudhry S, Patritti BL, Woodman R, Hakendorf P, Huang L. Goal attainment: a clinically meaningful measure of success of botulinum toxin-a treatment for lower limb spasticity in ambulatory patients. Arch. Rehabil. Res. Clin. Transl. 3(2), 100129 (2021).","journal-title":"Arch. Rehabil. Res. Clin. Transl."},{"issue":"1","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.51225","article-title":"Long-term adherence and response to botulinum toxin in different indications","volume":"8","author":"Lee JI","year":"2021","unstructured":"Lee JI, Jansen A, Samadzadeh S Long-term adherence and response to botulinum toxin in different indications. Ann. Clin. Transl. Neurol. 8(1), 15\u201328 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/13696998.2022.2092354","article-title":"The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia","volume":"25","author":"Danchenko N","year":"2022","unstructured":"Danchenko N, Johnston KM, Whalen J. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia. J. Med. Econ. 25(1), 919\u2013929 (2022).","journal-title":"J. Med. Econ."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:53:17Z","timestamp":1779285197000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.57264\/cer-2025-0181"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0181","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"e250181"}}